---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117682"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:09.909579+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome Q3 net loss $47.1M, cash $240.1M; AL102 topline data H2 2025

## Summary
- Net loss of $47.1M for Q3 2024; cash, equivalents and marketable securities $240.1M as of Sept 30, 2024.
- R&D expenses $37.2M; in-process R&D $6.7M (related to business development); G&A $9.5M.
- Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected H2 2025.
- IND submissions for IM-1021 and IM-3050 on track for Q1 2025.
- Cash runway expected to extend into 2026.

## SEC filing metadata
- accession: 0001104659-24-117682
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/0001104659-24-117682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/tm2428220d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117682
- JSON: https://secwatch.observer/filing/0001104659-24-117682.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.